Brilacidin exhibited potent in vitro antiviral activity against SARS-CoV-2
On Nov. 1, 2020, scientists announced that increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs),…
Lilly announced agreement with US government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab to fight COVID-19
On Oct. 28, 2020, Eli Lilly announced an initial agreement with the U.S. government to supply 300,000 vials…
Aspirin use best for those with high coronary calcium, low risk of bleeding
On Oct. 28, 2020, University of Texas (UT) Southwestern scientists reported that an X-ray test commonly used to…
Seagen announced closing of $1.0 billion stock sale to Merck
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
Biotechnology | Diagnostics | Disease | Genomics | Life Science News | NIH | Therapeutics
Scientists used clues in the human genome to discover new inflammatory syndrome
On Oct. 27, 2020, researchers from the National Institutes of Health (NIH) announced they had discovered a new…
ViralClear halted its phase 2 hospitalized COVID-19 trial
On Oct. 26, 2020, BioSig Technologies and its majority owned subsidiary, ViralClear Pharmaceuticals, announced the halting of its…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
FDA approved Gilead’s antiviral Veklury (remdesivir) for treatment of COVID-19
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
ViiV Healthcare analysis showed no antiretroviral therapy interruptions due to COVID-19
On Oct. 21, 2020, ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, announced…
Agriculture | Artificial Intelligence | Biotechnology | CMO | CRO | Life Science News | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
U.S. Department of Defense approved $87 million for newest bioindustrial manufacturing innovation institute
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Mateon’s phase 2 global study for OT-101/ TGF- Inhibitor against COVID-19 cleared for patient enrollment in Argentina
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and response
On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development…
Just – Evotec Biologics received grant to enable an antibody product for the prevention of COVID-19
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
Fred Hutch completed move-in of Lake Union Steam Plant
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
Mosquitoes’ taste for blood traced to four types of neurons
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
Biotechnology | COVID-19 | Disease | Life Science News | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $1.4 million to study COVID-19 in Latino Americans
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
SIGA announced Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX
On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an…
The Nobel Prize in Chemistry for 2020 was awarded to Emmanuelle Charpentier and Jennifer A Doudna
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Emmanuelle Charpentier and Jennifer Doudna…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
RedHill Biopharma opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…